Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer
Open Access
- 4 September 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (9) , e0222024
Abstract
The identification of biomarkers for predicting the responsiveness to eribulin in patients with metastatic breast cancer pretreated with an anthracycline and a taxane remains an unmet need. Here, we established a serum microRNA (miRNA)-based prediction model for the emergence of new distant metastases after eribulin treatment. Serum samples were collected from metastatic breast cancer patients prior to eribulin treatment and comprehensively evaluated by miRNA microarray. The prediction model for estimating eribulin efficacy was established using the logistic LASSO regression model. Serum samples were collected from 147 patients, of which 52 developed at least one new distant metastasis after eribulin monotherapy and 95 did not develop new distant metastases. A combination of eight serum miRNAs (miR-4483, miR-8089, miR-4755-3p, miR-296-3p, miR-575, miR-4710, miR-5698 and miR-3160-5p) predicted the appearance of new distant metastases with an area under the curve of 0.79, sensitivity of 0.69 and specificity of 0.82. The serum levels of miR-8089 and miR-5698 were significantly associated with overall survival after the initiation of eribulin treatment. The present study provides evidence that serum miRNA profiling may serve as a biomarker for the responsiveness to eribulin and for predicting the development of new distant metastases in metastatic breast cancer.Keywords
Funding Information
- National Cancer Center Research and Development Fund (29-A-1)
- Japan Agency for Medical Research and Development (18ae0101013h0005)
This publication has 27 references indexed in Scilit:
- Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancerHuman Pathology, 2017
- Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trialEuropean Journal of Cancer, 2017
- Circulating microRNAs and extracellular vesicles as potential cancer biomarkers: a systematic reviewInternational Journal of Clinical Oncology, 2017
- MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancerBreast Cancer Research and Treatment, 2017
- In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumabBritish Journal of Cancer, 2016
- Retracted: MicroRNA‐575 targets BLID to promote growth and invasion of non‐small cell lung cancer cellsFEBS Letters, 2015
- Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patientsAnnals of Hematology, 2014
- Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) statesBritish Journal of Cancer, 2014
- MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-à-go-go (EAG1)European Journal of Cancer, 2013
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011